Precigen, Inc.

PGEN·NasdaqGS·Healthcare
Compare
7.66−0.15 (−1.92%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close7.81
Open7.77
Day range7.637.87
52-week range3.048.98
Off day high−2.67%
Off 52-week high−14.70%
Volume2.16M
Avg. volume (3M)5.01M
Market cap2.74B
EPS (TTM)-1.06
Forward P/E-34.82
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.92
Shares outstanding358.04M
Short interest24.36% of float
Earnings dateAug 4, 2026
Analyst target13.65
Profit margin−183.98%

Against its peers

Compare in full ›
PGEN AUTL IDYA IMTX LEGN MRVI
Market cap 2.74B 463.12M 3.48B 1.10B 3.46B 2.61B
P/E (TTM) — — — — — —
Forward P/E -34.8 -2.8 -9.0 -3.5 17.0 -70.1
Price/book 62.8 6.2 2.9 2.2 2.8 5.1
Dividend yield — — — — — —
1-year change +139.38% +7.41% +33.21% −29.11% −46.43% +118.58%
Today −1.92% −3.87% −0.14% −2.96% −4.40% −5.11%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All PGEN news ›
Clinical Trials Arena·Positive

Surrozen secures FDA clearance for SZN-8141 clinical trial

Surrozen intends to dose the first patient in its DUET clinical trial during the fourth quarter of 2026. The US Food and Drug Administration (FDA) has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin…

Mugglehead·Positive

Surrozen gains FDA IND clearance for SZN-8141

Surrozen expects to dose DUET's first patient in Q4; clearance also meets a condition for a US$95.1M financing close around Oct. 20. A study of an experimental injection for diabetic macular edema can begin after Surrozen, Inc. NASDAQSRZN…

Zacks Investment Research·Positive

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Zacks Equity Research October 01, 2026 PGEN Quick QuotePGEN NRIX Quick QuoteNRIX Precigen, Inc. (PGEN Quick QuotePGEN - Free Report) shares soared 6.3% in the last trading session to close at $8.56. The move was backed by solid volume with…

Markets Daily·Positive

Comparing TScan Therapeutics (NASDAQ:TCRX) & Precigen (NASDAQ:PGEN)

Posted by Danessa Lincoln on Oct 1st, 2026 Precigen (NASDAQ:PGEN – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies…

From articles in the 4Search news index.

In the news

9mentions in 30 days
7with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.